Sabby group reports 9.9% Tempest Therapeutics (TPST) ownership block
Rhea-AI Filing Summary
Sabby Volatility Warrant Master Fund, Sabby Management, and Hal Mintz report a sizable position in Tempest Therapeutics. They collectively report beneficial ownership of 492,223 shares of Tempest Therapeutics common stock, representing 9.9% of the outstanding class as of the event date. All three reporting persons state they have shared power to vote and dispose of these shares and no sole voting or dispositive power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Tempest Therapeutics, indicating a passive investment intent.
Positive
- None.
Negative
- None.
Insights
Sabby entities disclose a passive 9.9% stake in Tempest Therapeutics.
Sabby Volatility Warrant Master Fund, Sabby Management, and Hal Mintz report beneficial ownership of 492,223 Tempest Therapeutics common shares, or 9.9% of the class. Voting and dispositive authority over these shares is reported as shared, with no sole power listed for any of the filers.
The Schedule 13G certification states that the position was not acquired and is not held to change or influence control of Tempest Therapeutics, which aligns with a passive-investor filing status. This distinguishes the filing from a control-seeking position that would typically be reported on a different schedule.
While a 9.9% stake is a meaningful ownership block, the filing emphasizes passive intent. Future position changes, if any, would generally be reflected in subsequent ownership reports rather than being implied here.